Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20646585 | 0.86 | MMP2 (0.46) | MMP2MMP9MMP12MMP1LMNA | |
| SCHEMBL8583445 | 0.76 | PNP (0.63) | MMP2MMP9MMP12MMP1NOS1 | |
| SCHEMBL1621986 | 0.74 | KMT2A (0.65) | MMP2MMP9MMP12MMP1LMNA | |
| SCHEMBL27433280 | 0.74 | RAB9A (0.50) | MMP2MMP9MMP12MMP1LMNA | |
| SCHEMBL3412144 | 0.73 | TDP1 (0.51) | MMP2MMP9MMP12MMP1LMNA | |
| SCHEMBL23812473 | 0.72 | TDP1 (0.61) | MMP2MMP9MMP12MMP1LMNA | |
| SCHEMBL24414086 | 0.72 | MAPT (0.55) | LMNAKMT2ATDP1SLC6A2SLC6A3 | |
| SCHEMBL24512522 | 0.71 | TDP1 (0.56) | MMP2MMP9MMP12MMP1LMNA | |
| SCHEMBL3919215 | 0.70 | TDP1 (0.71) | MMP2MMP9MMP12MMP1LMNA | |
| SCHEMBL19831699 | 0.70 | TDP1 (0.63) | MMP2MMP9MMP12MMP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016808-A1 | ANTI-EGFR COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016808-A1 | ANTI-EGFR COMBINATIONS FOR TREATING TUMORS | EGFR, ERBB3, ERBB2 | MMP2 510/4885MMP9 521/4885MMP12 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.